Open AccessA randomized controlled prospective study to assess the role of subconjunctival bevacizumab in primary pterygium surgery in Indian patients
Author(s) -
Priyanka Singh,
Lopa Sarkar,
Harinder Singh Sethi,
Vijay Gupta
Publication year - 2015
Publication title -
indian journal of ophthalmology/indian journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 51
eISSN - 1998-3689
pISSN - 0301-4738
DOI - 10.4103/0301-4738.171508
Subject(s) - medicine , pterygium , bevacizumab , conjunctiva , surgery , prospective cohort study , randomized controlled trial , visual acuity , ophthalmology , chemotherapy , pathology
Pterygium is an ocular surface disorder with prevalence rates ranges from 0.3% to 29% in different parts of the world. Vascular endothelial growth factor (VEGF) has been detected in increased amounts in pterygium epithelium, compared with normal conjunctiva. Bevacizumab is a recombinant, humanized anti-VEGF antibody suggested as a possible adjunctive therapy for pterygium excision that appears to have a role in prevention of recurrence. We conducted this study to evaluate the role of subconjunctival bevacizumab in primary pterygium surgery in Indian patients.